GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer R...( Data being made available on NCI Dat...),Health

Data being made available on NCI Database Could Save Drug Development Time

and Capital for Other Research Institutions

PHILADELPHIA, June 20 /PRNewswire-FirstCall/ -- Marking another positive step in the collaborative fight against cancer, GlaxoSmithKline (NYSE: GSK) announced today the release of genomic profiling data for over 300 cancer cell lines via the National Cancer Institute's cancer Bioinformatics Grid(TM) (caBIG(TM)). The caBIG(TM) initiative is a network of infrastructure and tools that enables the collection, analysis, and sharing of data and knowledge along the entire research pathway from laboratory bench to patient bedside. By releasing the cell line data via caBIG(TM), GSK could be enabling other cancer research institutions to save considerable drug development time and capital in their future cancer therapeutic research.

"These data are valuable for many avenues of cancer research, and we are pleased to share them with the cancer community," said Paolo Poletti, M.D., Senior Vice President, Oncology Medicines Development Center, R&D, GlaxoSmithKline. "Vast amounts of data are being generated in biomedical research and in order to realize the potential benefits of molecular medicine, scientists need to be able to access data in more timely and cost-efficient ways. The caBIG(TM) platform is an excellent tool to do just that."

With the advent of the human genome project, researchers have been able to identify, aggregate and analyze cancer cell line information in the laboratory. These breakthrough bodies of data have been used extensively in the discovery and development of novel cancer therapeutics.

According to Dr. Richard Wooster, Director of Translational Medicine Oncology, R&D,
'/>"/>